Cocrystal Pharma (Cocrystal Pharma) Debt-to-Asset : 0.06 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma Debt-to-Asset?

Cocrystal Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.24 Mil. Cocrystal Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.61 Mil. Cocrystal Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $31.26 Mil. Cocrystal Pharma's debt to asset for the quarter that ended in Dec. 2023 was 0.06.

Cocrystal Pharma Debt-to-Asset Historical Data

The historical data trend for Cocrystal Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Debt-to-Asset Chart

Cocrystal Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.01

0.06

Cocrystal Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	-	0.06

Competitive Comparison of Cocrystal Pharma's Debt-to-Asset

For the Biotechnology subindustry, Cocrystal Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Debt-to-Asset falls into.

Cocrystal Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cocrystal Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.24	+	1.613)	/	31.259
	=	0.06

Cocrystal Pharma's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.24	+	1.613)	/	31.259
	=	0.06

Cocrystal Pharma (NAS:COCP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cocrystal Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cocrystal Pharma (Cocrystal Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

8CC:Germany

Address

19805 North Creek Parkway, Bothell, WA, USA, 98011

Website

https://www.cocrystalpharma.com

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Executives

Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al	director, 10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi	director, 10 percent owner	1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin	officer: Interim CFO	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale	officer: INTERIM CFO	1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers	officer: CHIEF MEDICAL OFFICER	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott	officer: GENERAL COUNSEL AND SECRETARY	1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler	director	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block	director
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027